- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01540474
Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
Phase 1 Study With the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), an E.Coli-expressed Cell-Traversal Protein, Administered Intramuscularly in Healthy Malaria-Naive Adults
Malaria has remained a major concern for the US military. During World War II, malaria was the leading cause of disease and non-battle injury with 500-700 men infected per day, resulting in 24,000 malaria-related casualties.(10) Currently, the methods used for protecting troops against malaria are insecticidal nets, clothing, and antimalarial treatment. To be effective, these methods must be self-administered and be used consistently, often unattainable in field or combat situations. The United States Army Medical Research and Development Command (USAMRMC), through the United States Army Medical Materiel Development Activity (USAMMDA) and the Walter Reed Army Institute of Research (WRAIR) are actively pursuing the development of an effective vaccine against P. falciparum malaria; development of such a vaccine is a high priority for the US military and other individuals who travel to endemic regions, and is equally important to populations residing in those areas.
A Phase 1 study using FMP012, a recombinant E.coli expressed malaria protein (CelTOS) vaccine will
assess the safety and reactogenicity of candidate P. falciparum malaria vaccine FMP012/GLA-SE
Secondary:
- measure the humoral immune response to FMP012/GLA-SE using enzyme-linked immunosorbent assay (ELISA)
- assess the protective efficacy of FMP012/GLA-SE against a P. falciparum sporozoite challenge.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Silver Spring, Maryland, United States, 20910
- Clinical Trials Center, WRAIR
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- Healthy adults (male or non-pregnant, non-lactating female) 18 to 50 years of age at the time of screening
- If the subject is female,
- Non-childbearing potential , abstinent or using adequate contraceptive precautions during this study and must agree to continue such precautions until three months after challenge
- A negative pregnancy test at the time of enrollment
- Free of significant health problems as established by medical history, laboratory, and clinical examination before entering the study
- Low cardiac risk factors
- Available to participate and reachable by phone for duration of study (approximately 8 months)
- No plans to travel to outside the Washington DC area between the day of challenge and either completion of treatment course (post-challenge) or, if subject remains uninfected, 28 days post-challenge
- No plans to travel to a malaria endemic area during the course of the study
- Written informed consent must be obtained from the subject before screening procedures
- Subjects must score at least 80% correct on a multiple-choice quiz that assesses their understanding of this study
- Active duty military must obtain approval from his or her supervisor
Exclusion Criteria:
- History of malaria infection
- History of travel to P. falciparum endemic areas in the 3 months prior to day of first vaccination or day of challenge
- History of receiving a malaria vaccine
- Receipt of any licensed vaccine within 7 days prior to first vaccination
- History of receipt of malaria prophylaxis during the 2 months prior to day of first vaccination or day of challenge
- History of use of any drugs with significant antimalarial activity during the course of the study period
- Prior receipt of any vaccine containing either QS-21, MPL or GLA-SE in the previous 5 years (including Cervarix®, GSK)
- Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine or planned use during the study period.
- Any history of allergic reaction or anaphylaxis to previous vaccination
- Allergy to kanamycin, nickel, or imidazole Pregnant or lactating female at screening or plans to become pregnant or breastfeed from the time of enrollment until three months after challenge
- Allergy to antimalarial drugs or use of medications known to interact with both CQ and artemether/lumefantrine
- Significant (eg, systemic) hypersensitivity reactions to mosquito bites
- History of sickle cell disease
- History of psoriasis or porphyria
- History of splenectomy
- Any confirmed or suspected immunodeficiency, including HIV infection
- Administration of chronic (defined as more than 14 days) immunosuppressive drugs or other immune-modifying drugs within six months of vaccination
- Inhaled and topical steroids are allowed
- A family history of congenital or hereditary immunodeficiency
- Acute or chronic, clinically significant, pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by history, physical examination, or laboratory evaluation
- Chronic or active neurologic disease including seizure disorder and chronic migraine headaches
- Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or any planned administration during the study period
- Any abnormal baseline laboratory screening tests listed below (normal values are defined in the adverse event section of this protocol):
- Seropositive for HIV or Hepatitis C virus or HBsAg positive
- Hepatomegaly, right upper quadrant abdominal pain or tenderness
- An abnormal baseline screening EKG.
- Suspected or known current alcohol or drug abuse as determined from the medical history or by physical examination
- Any other significant finding that in the opinion of the PI would increase the risk of having an adverse outcome from participating in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1: 10 ug FMP012 with 2 ug GLA-SE
Single center, non-randomized, open label, dose escalation Phase 1 study with sporozoite challenge.
The antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion.
This is a first-in-human study of FMP012.
30 subjects, divided into 3 groups, will receive 3 doses of the FMP012/GLA-SE vaccine.
Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
|
Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
|
Experimental: Group 2: 10 ug FMP012 with 5 ug GLA-SE
Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
|
E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
|
Experimental: Group 3: 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE
Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
|
E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
|
Other: Control group-Challenged Only
Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
|
The control group participated in the primary malaria sporozoite challenge.E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Solicited or Unsolicited Symptoms Reporting During the Post-vaccination Period
Time Frame: From vaccination day through 7 days post vaccination (for all three doses)
|
Number of participants for each dose (1 through 3) that experienced any symptom, general solicited symptoms, and local solicited symptoms
|
From vaccination day through 7 days post vaccination (for all three doses)
|
Number of Participants With Solicited or Unsolicited Symptoms Reporting During the Post-vaccination Period
Time Frame: From vaccination day through 7 days post vaccination for each does (1-3)
|
Incidence of erythema and pain (solicited local symptoms) reported after each dose (1-3) of vaccination.
Results for groups 1, 2 and 3 only as control group did not receive any vaccinations and only participated in the malaria challenge portion of the study.
|
From vaccination day through 7 days post vaccination for each does (1-3)
|
Subjects Reporting the Occurrence of Unsolicited Adverse Events Related to Vaccination
Time Frame: 28 days after each vaccination
|
Number of participants with at lease one administered dose presenting with at least one specified symptom within 28 days after vaccination
|
28 days after each vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Humoral Immune Response to FMP012/GLA-SE
Time Frame: Up to 1 year
|
Seroconversion was defined as a post-second vaccination titer (serum dilution of 1:100) that is 3 standard deviations higher than the average of the negative or pre-vaccination serum measured using enzyme-linked immunosorbent assay (ELISA). Values reported as "below the detection limit" were given a value of 50 units. The safety population was used for immunogenicity analysis. Only subjects who received vaccinations or were challenged were included in the analysis of immunogenicity. Subjects who withdrew from the study had data collected to the point of withdraw. Geometric mean titers (GMT) were obtained by first calculating the mean and 95% confidence intervals for log-transformed values of the ELISA results, followed by exponentiation of the values. Among those vaccinated, all values were below the detection limit until post-dose II. |
Up to 1 year
|
Time to Onset of Parasitemia Following Sporozoite Challenge
Time Frame: Up to 1 year
|
Protective Efficacy of FMP012/GLA-SE Measured against a P falciparum sporozoite challenge.
Vaccinated subjects were compared to infectivity controls to assess for delayed onset of parasitemia.
Time of onset of parasitemia was based on the date of sporozoite challenge to the date of first positive blood smear detection.
|
Up to 1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jessica J. Cowden, MD, Walter Reed Army Institute of Research (WRAIR)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- S-11-21
- IND 014962 (Other Identifier: WRAIR)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Group 1: 10 ug FMP012 with 2 ug GLA-SE
-
Pontificia Universidad Catolica de ChileUnknownSurgery | Nerve Block | Anesthetic Toxicity | Anesthetics Complications | Bupivacaine OverdoseChile
-
University Hospital, Strasbourg, FranceUnknownPercutaneous Tumor AblationFrance
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAcute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic LeukemiaUnited States